Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 11:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 318 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: amphetamine Clear all
Terminated Phase 2 Interventional Results available

Impact of Combined Medication and Behavioral Treatment for ASD & ADHD

NCT03242772
View directory record Official record
Conditions
Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder
Interventions
Amphetamine, ESDM informed parent coaching, Placebo Oral Tablet
Drug · Behavioral
Lead sponsor
Duke University
Other
Eligibility
36 Months to 131 Months
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 22, 2022 · Synced Oct 21, 2026, 11:10 PM EDT
Completed Phase 2 Interventional

Bupropion for the Treatment of Methamphetamine Dependence - 1

NCT00069251
View directory record Official record
Conditions
Amphetamine-Related Disorders
Interventions
Bupropion
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
5
States / cities
Costa Mesa, California • San Diego, California • Honolulu, Hawaii + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 21, 2026, 11:10 PM EDT
Recruiting Phase 2 Interventional

MDMA-assisted Cognitive Processing Therapy Versus Cognitive Processing Therapy for Veterans With Severe Posttraumatic Stress Disorder

NCT05837845
View directory record Official record
Conditions
PTSD
Interventions
MDMA, Cognitive Processing Therapy, MDMA-assisted Cognitive Processing Therapy (MDMA-aCPT)
Drug · Behavioral
Lead sponsor
Patricia Suppes
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Oct 21, 2026, 11:10 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Treatment of Cannabis Use Disorder Among Adults With Comorbid Attention-Deficit/Hyperactivity Disorder

NCT02803229
View directory record Official record
Conditions
Cannabis Use Disorder, Attention-deficit/Hyperactivity Disorder
Interventions
Adderall-XR, Matched placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 9, 2021 · Synced Oct 21, 2026, 11:10 PM EDT
Recruiting Phase 2 Interventional

A Phase 2A Trial of DT402 for Autism Spectrum Disorder

NCT07303907
View directory record Official record
Conditions
Autism Spectrum Disorder, ASD
Interventions
DT402 (R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA))
Drug
Lead sponsor
Definium Therapeutics US, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 21, 2026, 11:10 PM EDT
Completed No phase listed Observational

IMPAACT P1080: Psychiatric and Antiretroviral Medication Concentrations in HIV-infected and Uninfected Children and Adolescents

NCT01232361
View directory record Official record
Conditions
ADHD, HIV
Interventions
Not listed
Lead sponsor
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Network
Eligibility
6 Years to 25 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
21
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Oct 21, 2026, 11:10 PM EDT
Recruiting Phase 2 Interventional

MDMA-Assisted Massed Exposure Therapy for PTSD

NCT07288151
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
3,4-Methylenedioxymethamphetamine (MDMA), Placebo, Massed Prolonged Exposure (PE)
Drug · Behavioral
Lead sponsor
Emory University
Other
Eligibility
21 Years to 70 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 21, 2026, 11:10 PM EDT
Completed Phase 4 Interventional

Medication Strategies for Treating Aggressive Behavior in Youth With Attention Deficit Hyperactivity Disorder

NCT00228046
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity, Conduct Disorder, Oppositional Defiant Disorder
Interventions
Divalproex Sodium, Methylphenidate, Dextroamphetamine, Mixed Amphetamine Salts, Family Counseling, Behavior Management Training with Parents
Drug · Behavioral
Lead sponsor
Stony Brook University
Other
Eligibility
6 Years to 14 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
New Hyde Park, New York • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Oct 31, 2013 · Synced Oct 21, 2026, 11:10 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of Brain Changes Shaped by Experience

NCT00006424
View directory record Official record
Conditions
Healthy, Neurologic Manifestations
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 21, 2026, 11:10 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Prosocial Effects of MDMA

NCT05948683
View directory record Official record
Conditions
MDMA ('Ecstasy'), Social Interaction
Interventions
MDMA, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 35 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 21, 2026, 11:10 PM EDT
Completed Phase 2 Interventional

A Pilot Trial of Dextroamphetamine for Methamphetamine Dependence

NCT00630682
View directory record Official record
Conditions
Methamphetamine Addiction
Interventions
Dextroamphetamine, Placebo
Drug
Lead sponsor
California Pacific Medical Center Research Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced Oct 21, 2026, 11:10 PM EDT
Enrolling by invitation No phase listed Observational

Stimulant and Polysubstance Use, Inflammation, and Sex Effects on Myocardial Disease in HIV

NCT07461350
View directory record Official record
Conditions
HIV (Human Immunodeficiency Virus)
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
30 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
4
States / cities
San Francisco, California • Atlanta, Georgia • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 21, 2026, 11:10 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Drugs Brain and Behavior (DDP)

NCT04642820
View directory record Official record
Conditions
Stimulant Use
Interventions
Methamphetamine, placebo oral tablet
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 35 Years
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 9, 2025 · Synced Oct 21, 2026, 11:10 PM EDT
Recruiting Phase 2 Interventional

MDMA-Assisted CBT for OCD (MDMA-CBT4OCD Study)

NCT05783817
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
3,4-Methyl enedioxy methamphetamine, Methamphetamine, Cognitive Behavioral Therapy (CBT)
Drug · Behavioral
Lead sponsor
Carolyn Rodriguez
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 21, 2026, 11:10 PM EDT
Terminated Phase 3 Interventional Results available

Long-term Safety of SPD489 When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia

NCT01760993
View directory record Official record
Conditions
Schizophrenia
Interventions
SPD489
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
2
States / cities
Oklahoma City, Oklahoma • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Oct 21, 2026, 11:10 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Study of DYANAVEL XR (Amphetamine) Extended-release Oral Suspension, in Children Aged 4 to 5 Years

NCT03610464
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Amphetamine Extended Release Suspension [Dyanavel]
Drug
Lead sponsor
Tris Pharma, Inc.
Industry
Eligibility
4 Years to 5 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Maitland, Florida
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Oct 21, 2026, 11:10 PM EDT
Completed Phase 3 Interventional Results available

SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder

NCT01718483
View directory record Official record
Conditions
Binge Eating Disorder
Interventions
SPD489 (Lisdexamfetamine dimesylate), Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
383 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
43
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Corona, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Oct 21, 2026, 11:10 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Neuroimaging Study of Risk Factors for Adolescent Bipolar Disorder

NCT02478788
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
mixed amphetamine salts-extended release (MAS-XR), Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
10 Years to 18 Years
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 21, 2026, 11:10 PM EDT
Completed Phase 2 Interventional

A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects

NCT00402077
View directory record Official record
Conditions
Overweight, Obesity
Interventions
pramlintide acetate, sibutramine, phentermine, placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
16
States / cities
Birmingham, Alabama • Phoenix, Arizona • Chula Vista, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 21, 2026, 11:10 PM EDT
Completed Phase 1 Interventional Results available

Lisdexamfetamine Dimesylate (LDX) Pilot Cognition Study to Evaluate the Utility of a Standardized Battery of Tests in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

NCT01010750
View directory record Official record
Conditions
Attention-Deficit Hyperactivity Disorder
Interventions
Lisdexamfetamine Dimesylate (LDX), Immediate Release Mixed Amphetamine Salts (MAS-IR), LDX Placebo + MAS-IR Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 21, 2026, 11:10 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

IMProving Executive Function Study

NCT03187353
View directory record Official record
Conditions
Cognitive Impairment, RRSO
Interventions
Lisdexamfetamine, Placebo oral capsule
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
35 Years to 58 Years · Female only
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 21, 2026, 11:10 PM EDT
Completed Phase 2 Interventional Results available

Effects of Co-administration of Canagliflozin 300 mg and Phentermine 15 mg With Placebo in the Treatment of Non-Diabetic Overweight and Obese Participants

NCT02243202
View directory record Official record
Conditions
Obesity
Interventions
Canagliflozin, Phentermine, Matching Placebo to Canagliflozin, Matching Placebo to Phentermine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
17
States / cities
Phoenix, Arizona • Walnut Creek, California • Jacksonville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2016 · Synced Oct 21, 2026, 11:10 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Amphetamine Extended-Release Tablets in the Treatment of Adults With ADHD

NCT03834766
View directory record Official record
Conditions
ADHD
Interventions
AMPH ER Tab 5, 10, 15 and 20 mg, AMPH ER Tab Matching Placebo 5, 10, 15 and 20 mg
Drug
Lead sponsor
Tris Pharma, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
3
States / cities
Bradenton, Florida • Maitland, Florida • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Oct 21, 2026, 11:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect of Stimulant Drugs on Social Perception

NCT03790618
View directory record Official record
Conditions
Healthy, MDMA ('Ecstasy')
Interventions
3,4-Methylenedioxymethamphetamine, methamphetamine
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 35 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 5, 2024 · Synced Oct 21, 2026, 11:10 PM EDT